Blockade of placental growth factor reduces vaso-occlusive complications in murine models of sickle cell disease

- Blockade of plasma placental growth factor (PlGF) in sickle cell disease (SCD) mice decreases plasma pro-inflammatory biomarker levels.
- Blockade of PlGF in SCD mice reduces plasma lactate dehydrogenase levels and organ congestion.
- Blockade of PlGF in SCD mice reduces vascular stasis in the dorsal skinfold chamber model.
- Blockade of PlGF is a potential therapeutic approach for SCD.